{"id":"NCT02807636","sponsor":"Hoffmann-La Roche","briefTitle":"Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma","officialTitle":"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-30","primaryCompletion":"2022-08-31","completion":"2024-02-12","firstPosted":"2016-06-21","resultsPosted":"2023-12-13","lastUpdate":"2025-02-24"},"enrollment":1213,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urothelial Carcinoma"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin","type":"EXPERIMENTAL"},{"label":"Placebo+Gemcitabine+Carboplatin/Cisplatin","type":"PLACEBO_COMPARATOR"},{"label":"Atezolizumab Monotherapy","type":"EXPERIMENTAL"}],"summary":"A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.","primaryOutcome":{"measure":"Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm","timeFrame":"Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)","effectByArm":[{"arm":"Placebo+Gemcitabine+Carboplatin/Cisplatin","deltaMin":6.34,"sd":null},{"arm":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin","deltaMin":8.18,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0073"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":25},"locations":{"siteCount":204,"countries":["United States","Australia","Belgium","Bosnia and Herzegovina","Brazil","Canada","Chile","China","Czechia","Estonia","Finland","Georgia","Greece","Hong Kong","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovenia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38280376","38101433","38101431","37954037","32416780","27939400"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":197,"n":389},"commonTop":["Anaemia","Nausea","Neutropenia","Decreased appetite","Fatigue"]}}